Product
Tildrakizumab
Aliases
Ilumetri®, Pregnant women exposed to tildrakizumab, Pregnant women not exposed to tildrakizumab
17 clinical trials
13 indications
Indication
Pregnancy RelatedIndication
Chronic Plaque PsoriasisIndication
PsoriasisIndication
Nail PsoriasisIndication
Psoriasis VulgarisIndication
Skin and Connective Tissue DiseasesIndication
Skin DiseasesIndication
Pigmentation DisorderIndication
HypopigmentationIndication
Biological agentIndication
VitiligoIndication
Hematologic MalignanciesClinical trial
Post-authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Placebo and Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2031-05-23
Clinical trial
Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland, and the Czech RepublicStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and SwitzerlandStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2021-11-02
Clinical trial
A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
An International, Multicentre, Open- Label, Interventional Phase IV Clinical Study to Investigate the Efficacy and Safety of Tildrakizumab 100 mg in Patients With Moderate- Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)Status: Completed, Estimated PCD: 2021-11-15
Clinical trial
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype PsoriasisStatus: Completed, Estimated PCD: 2021-06-07
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail PsoriasisStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Predicting Inflammatory Skin Disease Response to IL-23 BlockadeStatus: Completed, Estimated PCD: 2023-01-15
Clinical trial
Pilot Study Assessing the Effect of Tildrakizumab in VitiligoStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Effects of Tildrakizumab on Coronary Microvascular Function in Moderate-Severe PsoriasisStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio StudyStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Psoriatic Immune Response to TildrakizumabStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Status: Terminated, Estimated PCD: 2023-04-01